Lupin lands sole US interchangeable biosimilar for Roche's Lucentis
The FDA approval for Ranluspec makes Lupin's product the only interchangeable ranibizumab biosimilar in the United States, a key regulatory distinction in the crowded eye-drug market.
— 3 earlier stories on Lupin Ltd. →What's new
- Lupin won FDA approval for Ranluspec, a biosimilar to Roche's Lucentis for retinal diseases.
- The product is the only interchangeable ranibizumab biosimilar approved in the United States.
- It will be sold in vials and pre-filled syringes across two strengths.
Why this matters
Interchangeable status is a meaningful differentiator in the US biosimilars market. It means pharmacies can often substitute Ranluspec for the reference product without the prescriber's intervention, a convenience that can drive faster uptake. This is Lupin's second US biosimilar approval, adding a higher-margin complex biologic to its pipeline.
What we're watching
- The US launch timeline and initial market-access contracts for Ranluspec.
- Pricing strategy relative to other ranibizumab biosimilars already on the market.
- How the interchangeability status translates into actual pharmacy-level substitution rates.
The full read
Lupin has a new asset in the US market: Ranluspec, a biosimilar to Roche's blockbuster eye drug Lucentis. The key detail is that the FDA granted it interchangeable status, a regulatory distinction no other ranibizumab biosimilar in the US holds. That means pharmacists can often switch patients to Ranluspec without a new prescription, a practical advantage aimed at capturing substitution from the originator. The product will launch in vials and pre-filled syringes. The approval is strategically important for Lupin's push into complex biologics and marks its second US biosimilar win. The open question is the commercial impact. The filing discloses no revenue projections or market sizing. For a company of Lupin's scale, the approval is a pipeline addition, not a game-changer by itself.
Questions answered
- What does 'interchangeable' mean for a biosimilar?
- An interchangeable biosimilar can be substituted by a pharmacist for the reference biologic without the prescribing doctor's involvement, subject to state pharmacy laws. This regulatory designation is designed to ease the switch from the original drug, potentially speeding up adoption.
- What is the reference product for Ranluspec?
- Ranluspec references Lucentis (ranibizumab), a blockbuster eye drug originally marketed by Roche and Novartis. It is used to treat wet age-related macular degeneration and diabetic macular edema.
- How significant is this approval for Lupin's overall business?
- The approval adds a second biosimilar to Lupin's US portfolio. However, the filing contains no financial details on market size, revenue potential, or expected impact on Lupin's annual revenue of over ₹27,500 crore.
Story so far
All notes on LUPIN →- 4 Jun 2026 · 11:07 PM IST Lupin lands sole US interchangeable biosimilar for Roche's Lucentis
- 1d ago Lupin wins US FDA nod for generic Halaven, but the prize is tiny
- 6d ago Lupin lands six-month U.S. monopoly on colonoscopy drug Sutab
- 13d ago Lupin wins its first drug approval in China